ProShares UltraShort MidCap400
6 hedge funds and large institutions have $1.04M invested in ProShares UltraShort MidCap400 in 2017 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and closing their positions.
20% more funds holding
Funds holding: 5 → 6 (+1)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
2.75% less ownership
Funds ownership: 9.68% → 6.92% (-2.8%)
49% less capital invested
Capital invested by funds: $2.04M → $1.04M (-$1.01M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$17.4K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$6.39K |
| 3 |
Simplex Trading
Chicago,
Illinois
|
+$3.95K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
-$671K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$173K |
MZZ Hedge Fund Activity: Q4 2017 in Review
6 of the 4,386 institutional investors tracked by Wall St. Rank reported a position in ProShares UltraShort MidCap400 (MZZ) for Q4 2017, worth a combined $1.04M — down 49% from $2.04M a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new MZZ positions and 0 closed out — a net gain of 1 holder — while 2 added to existing stakes and 2 trimmed.
The largest buyer was UBS Group, adding an estimated $17.4K. The largest seller was Tower Research Capital (TRC), cutting an estimated $671K.
- 6 institutional investors held ProShares UltraShort MidCap400 (MZZ) as of Q4 2017, up from 5 in Q3 2017.
- Funds reported $1.04M of ProShares UltraShort MidCap400 stock for Q4 2017, down 49% quarter-over-quarter.
- 1 fund opened new ProShares UltraShort MidCap400 positions in Q4 2017 and 0 closed out, a net change of +1 holder.
- The largest ProShares UltraShort MidCap400 buyer in Q4 2017 was UBS Group, an estimated $17.4K added.
- The largest ProShares UltraShort MidCap400 seller in Q4 2017 was Tower Research Capital (TRC), an estimated $671K sold.
Based on aggregated 13F filings for Q4 2017.